Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.500
+0.070 (+4.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Marinus Pharma's Earnings Outlook
March 04, 2024
Via
Benzinga
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 16, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) is a Stock Spotlight on 1/5
January 05, 2024
Via
Investor Brand Network
Analyst Expectations for Marinus Pharma's Future
December 05, 2023
Via
Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Analyst Ratings for Marinus Pharma
September 20, 2023
Via
Benzinga
Analyst Ratings for Marinus Pharma
August 11, 2023
Via
Benzinga
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
November 20, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 14, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Preview: Marinus Pharma
August 09, 2023
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
November 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 20, 2023
Via
Benzinga
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
September 19, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
September 12, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
August 17, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 11, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
August 11, 2023
Via
Benzinga
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
August 11, 2023
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.